Personalizing Care for Nonalcoholic Fatty Liver Disease Patients: What Are the Research Priorities?

Silvia Sookoian; Carlos J Pirola


Personalized Medicine. 2014;11(8):735-743. 

In This Article

Future Perspective

The field will evolve in the future by targeting an integrative approach of NAFLD diagnosis and therapeutics. For instance, the application in the clinical setting of a multi-scoring panel that not only minimizes the need for a liver biopsy for distinguishing between simple steatosis and NASH but also predicts a patient's global metabolic risk might be combined with a patient's genetic make-up and other data gathered from omics technologies to choose the right therapeutic program and to predict the individual chances of response (Figure 1). This personalized diagnosis will improve our capability to understand the disease biology and allow us to deal with a tailored medical intervention. Whether this strategy will evolve from whole-genome sequencing is not known. Nevertheless, practical implementation of this kind of approach together with the limitations of these technologies remains an enormous challenge.